RAPT Therapeutics, Inc. (RAPT)

RAPT Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	1.53	3.81	5.04
Revenue Growth (YoY)	-	-	-59.95%	-24.38%	-
Gross Profit	-	-	1.53	3.81	5.04
Selling, General & Admin	28.88	26.06	20.24	16.04	12.77
Research & Development	107.22	101	67.08	56.99	45.49
Operating Expenses	136.1	127.06	87.32	73.02	58.26
Operating Income	-136.1	-127.06	-85.8	-69.21	-53.21
Other Non Operating Income (Expenses)	3.42	4.53	1.66	1.28	1.81
EBT Excluding Unusual Items	-132.68	-122.53	-84.13	-67.93	-51.41
Gain (Loss) on Sale of Investments	2.81	5.74	0.3	-1.27	-0.5
Pretax Income	-129.87	-116.8	-83.84	-69.2	-51.9
Income Tax Expense	-	-	-	-	0.99
Net Income	-129.87	-116.8	-83.84	-69.2	-52.89
Net Income to Common	-129.87	-116.8	-83.84	-69.2	-52.89
Shares Outstanding (Basic)	41	38	33	27	24
Shares Outstanding (Diluted)	41	38	33	27	24
Shares Change (YoY)	6.32%	17.82%	18.80%	13.49%	455.27%
EPS (Basic)	-3.19	-3.05	-2.58	-2.53	-2.19
EPS (Diluted)	-3.19	-3.05	-2.58	-2.53	-2.19
Free Cash Flow	-83.42	-98.17	-71.62	-61.78	-40.89
Free Cash Flow Per Share	-2.05	-2.56	-2.20	-2.26	-1.69
Gross Margin	-	-	100.00%	100.00%	100.00%
Operating Margin	-	-	-5618.53%	-1815.08%	-1055.41%
Profit Margin	-	-	-5490.37%	-1814.95%	-1049.03%
Free Cash Flow Margin	-	-	-4689.98%	-1620.27%	-810.97%
EBITDA	-134.9	-125.85	-84.75	-68.21	-52.09
D&A For EBITDA	1.2	1.22	1.05	1	1.12
EBIT	-136.1	-127.06	-85.8	-69.21	-53.21

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q